Impact of the addition of bevacizumab, oxaliplatin or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.

被引：0
|
作者：
Landre, Thierry
Aparicio, Thomas
Ghebriou, Djamel
Nicolas, Patrick
Taleb, Cherifa
Chouahnia, Kader
Zelek, Laurent H.
Des Guetz, Gaetan
机构：
[1] Hop Rene Muret, APHP, HUPSSD, UCOG 93, Sevran, France
[2] St Louis Hosp, Dept Gastroenterol, Paris, France
[3] Ctr Hosp Argenteuil, Argenteuil, France
[4] Hop Avicenne, HUPSSD, Paris 13, France
[5] Hop Rene Muret, APHP, HUPSSD, Geriatr Oncol Unit, Sevran, France
[6] CHU Avicenne, Bobigny, France
[7] Hop Avicenne, Bobigny, France
[8] CHU Limoges, Serv Oncol Med, Limoges, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15034
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients
    Landre, Thierry
    Maillard, Emilie
    Taleb, Cherifa
    Ghebriou, Djamel
    Des Guetz, Gaetan
    Zelek, Laurent
    Aparicio, Thomas
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2018, 33 (08) : 1125 - 1130
  • [2] Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients
    Thierry Landre
    Emilie Maillard
    Chérifa Taleb
    Djamel Ghebriou
    Gaetan Des Guetz
    Laurent Zelek
    Thomas Aparicio
    International Journal of Colorectal Disease, 2018, 33 : 1125 - 1130
  • [3] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    M J Safont
    A Salud
    F Losa
    C García-Girón
    C Bosch
    P Escudero
    R López
    C Madroñal
    M Bolaños
    M Gil
    A Llombart
    J Castro-Carpeño
    M González-Barón
    British Journal of Cancer, 2010, 102 : 1468 - 1473
  • [4] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Safont, M. J.
    Salud, A.
    Losa, F.
    Garcia-Giron, C.
    Bosch, C.
    Escudero, P.
    Lopez, R.
    Madronal, C.
    Bolanos, M.
    Gil, M.
    Llombart, A.
    Castro-Carpeno, J.
    Gonzalez-Baron, M.
    BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1468 - 1473
  • [5] Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
    P García-Alfonso
    A J Muñoz-Martin
    S Alvarez-Suarez
    Y Jerez-Gilarranz
    M Riesco-Martinez
    P Khosravi
    M Martin
    British Journal of Cancer, 2010, 103 : 1524 - 1528
  • [6] Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
    Garcia-Alfonso, P.
    Munoz-Martin, A. J.
    Alvarez-Suarez, S.
    Jerez-Gilarranz, Y.
    Riesco-Martinez, M.
    Khosravi, P.
    Martin, M.
    BRITISH JOURNAL OF CANCER, 2010, 103 (10) : 1524 - 1528
  • [7] Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    J Barriuso
    British Journal of Cancer, 2011, 104 : 226 - 226
  • [8] Comment on 'Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer'
    Molina-Garrido, M. J.
    Guillen-Ponce, C.
    BRITISH JOURNAL OF CANCER, 2011, 104 (01) : 224 - 225
  • [9] Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
    M J Molina-Garrido
    C Guillén-Ponce
    British Journal of Cancer, 2011, 104 : 224 - 225
  • [10] Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Barriuso, J.
    BRITISH JOURNAL OF CANCER, 2011, 104 (01) : 226 - 226
12345